| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology | ||
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology | ||
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
Ovid Therapeutics Inc.$2.32
+0.1 (+4.44%)
Market Cap
461.00 M
EPS
-0.24
P/E Ratio
-
Value Trade
5.16 M
SEC Financials
Q1 2026Dilution Risk
Revenue
-
R&D Expenses
11.18 M
Operating CF
-13.90 M
Total Assets
225.63 M
Total Liabilities
27.36 M
Equity
198.27 M
D/E Ratio
12,345
-11.94 %
Week
-13.94 %
1 Month
63.58 %
3 Month
99.19 %
6 Month
-36.99 %
5 Year
-82.36 %
All Time
Cash Data
Cash Position
155.52 M
Monthly Burn
4.63 M
Runway
32.4 mo
Burn Trend
SEC Filing
May 12, 2026
Overview
Volume
2.42 M
52 Week Range
0.27 - 3.11
% held by Insiders
9.52 %
% held by Institutions
58.84 %
Enterprise Value
318.55 M
Total Shares
130.24 M
Short %
6.3 %
Float Shares
97.68 M
Company Description
locked
Upcoming Catalyst
Drug Pipeline Intelligence
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
OV329 | treatment-resistant seizures,pain | Phase 1 | 2025-08-14 | |||
OV329 | treatment-resistant seizures,pain | Phase 1 | 2025-08-14 | |||
OV329 | treatment-resistant seizures,pain | Phase 1 | 2025-08-14 |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in OVID
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
Ovid Therapeutics Inc. (OVID) Analyst Ratings & Price Targets
Symbol
Firm
Rating
Action
Price Target
Upside
date
OVID
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
OVID
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
OVID
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
OVID Stock Forecast & Analyst Consensus
BUY
Analyst Ratings
Buy65.0%
Hold25.0%
Sell10.0%
Price Target Trend
Average$24.00
Low$18.00
High$32.00
OVID Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-08-21 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2026-08-21 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2026-08-21 | 0.00 | 0 | - | - | - | - | - | - | ||||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
OVIDOvid Therapeutics to Participate in Upcoming Investor Conferences
NEW YORK, June 04, 2026 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (Nasdaq: OVID), a biopharmaceutical company dedicated to pioneering better, gentler medicines for brain disorders with significant unmet need, today announced that the Company’s management will participate in two
Read more →OVIDOvid Therapeutics Appoints Leading Physician-Scientist and Biotech Innovator Anna Greka, M.D., Ph.D., to Board of Directors
Ovid Therapeutics has appointed Dr. Anna Greka to its Board of Directors, effective June 15, 2026. Dr. Greka, a renowned physician-scientist, brings over 25 years of experience in advancing biological discoveries into clinical-stage therapies. She will chair the newly formed Science and Technology Committee and contribute to the Compensation Committee.
Read more →OVIDOvid Therapeutics Reports Business Updates and First Quarter 2026 Financial Results
Ovid Therapeutics reported positive business updates and financial results for Q1 2026, highlighting the initiation of a Phase 1 study for OV4071 and favorable results for OV329. The company plans to expand OV329's development into pediatric indications and has strengthened its financial position with significant capital raised. However, it also reported a net loss and increased expenses compared to the previous year.
Read more →OVIDOvid Therapeutics to Host Potassium-Chloride Co-transporter 2 (KCC2) Deep Dive R&D Event on Tuesday, April 14
Ovid Therapeutics will host a KCC2 Deep Dive R&D event on April 14, 2026, in New York. The event will showcase their first-in-class KCC2 portfolio, including direct activators for various neurological disorders. Leading experts will discuss pharmacodynamic data and the clinical development strategy. A live webcast will be available for participants.
Read more →OVIDOvid Therapeutics Announces Pricing of $60 Million Private Placement
Proceeds expected to support expansion of next-generation GABA-aminotransferase inhibitor, OV329, into tuberous sclerosis complex and infantile spasms Financing led by Point72 with participation from additional investors including Adage Capital Management, ADAR1 Capital Manageme
Read more →OVIDOvid Therapeutics Announces New OV329 Data and Indication Expansion, Phase 1 Clearance for OV4071, and Reports Fourth Quarter and Full Year 2025 Financial Results The 7 mg dose of OV329 demonstrated favorable safety and
Ovid Therapeutics Announces New OV329 Data and Indication Expansion, Phase 1 Clearance for OV4071, and Reports Fourth Quarter and Full Year 2025 Financial Results The 7 mg dose of OV329 demonstrated favorable safety and tolerability profile, reinforcing best-in-category potenti
Read more →OVIDOvid Therapeutics Reports Phase 1 Results for the First-Ever Direct Activator of Potassium-Chloride Cotransporter 2 (KCC2), OV350 Intravenous (IV) OV350 showed a good safety profile, supporting the advancement of the Com
Ovid Therapeutics Reports Phase 1 Results for the First-Ever Direct Activator of Potassium-Chloride Cotransporter 2 (KCC2), OV350 Intravenous (IV) NEW YORK, December 18, 2025 - Ovid Therapeutics Inc. (Nasdaq: OVID), a biopharmaceutical company developing small molecule medicin
Read more →OVIDOvid Therapeutics Appoints Dr. Petra Kaufmann as Chief Medical Officer
Ovid Therapeutics has appointed Dr. Petra Kaufmann as Chief Medical Officer. Dr. Kaufmann, with a strong background in CNS therapeutics and regulatory experience, will guide Ovid's clinical and medical strategies. Her expertise is expected to enhance the development of Ovid's pipeline, including the next-generation GABA-AT inhibitor, OV329.
Read more →OVIDOvid Therapeutics Announces Planned Leadership Succession and Reports Business Updates and Third Quarter 2025 Financial Results
Ovid Therapeutics announced a leadership succession plan with Meg Alexander set to become CEO on January 1, 2026, while Dr. Jeremy M. Levin transitions to Executive Chairman. The company reported strong financial results for Q3 2025 and highlighted advancements in its clinical pipeline, particularly with OV329 and KCC2 programs. Ovid is positioned for significant developments in the coming months.
Read more →OVIDOvid Therapeutics Announces Pricing of Private Placement Totaling up to $175 Million in Gross Proceeds
Ovid Therapeutics has announced a private placement financing expected to yield up to $175 million in gross proceeds. The financing includes participation from both new and existing investors and is set to close around October 6, 2025. Proceeds will be utilized for research and development, corporate expenses, and working capital needs.
Read more →OVIDOvid announces positive topline results for the next-generation GABA-aminotransferase inhibitor, OV329, that demonstrate strong inhibitory activity and a potential best-in-category safety profile
Ovid Therapeutics announced positive topline results from a Phase 1 study of OV329, a next-generation GABA-aminotransferase inhibitor aimed at treating drug-resistant epilepsies. The trial demonstrated OV329's safety, tolerability, and pharmacodynamic activity, with a favorable safety profile. The results indicate potential for further development in patient studies, reinforcing OV329's therapeutic promise.
Read more →OVIDOvid Therapeutics Reports Business Updates and Second Quarter 2025 Financial Results
Ovid Therapeutics has reported positive advancements in its clinical pipeline, including the upcoming Phase 1 readout for OV329, a GABA-AT inhibitor aimed at treating drug-resistant seizures. The company also plans to initiate a Phase 1/1b study for OV4071 in early 2026. Additionally, Ovid has strengthened its financial position through the sale of ganaxolone royalty rights, allowing for continued focus on its innovative small molecule therapies.
Read more →OVIDOvid Therapeutics to Participate in the BTIG Virtual Biotech Conference
Ovid Therapeutics Inc. will participate in the BTIG Virtual Biotechnology Conference on July 29-30, 2025. The company is dedicated to developing small molecule medicines for brain conditions with significant unmet needs. Their pipeline includes several promising candidates aimed at treating neurological and neuropsychiatric disorders.
Read more →OVIDOvid Therapeutics Enters Agreement with Immedica Pharma AB for Sale of Future Ganaxolone Royalties
Ovid Therapeutics has entered a definitive agreement with Immedica Pharma AB for the sale of future royalties related to ganaxolone outside of China. Immedica will pay $7 million to acquire these rights, providing Ovid with non-dilutive capital to support ongoing operations. The transaction does not impact Ovid's current pipeline, as the company is not pursuing further development of ganaxolone.
Read more →OVIDOvid Therapeutics to Host Investor and Media Event Thursday, June 12, 2025
Ovid Therapeutics will host an investor and media event on June 12, 2025, focusing on the application of biomarkers in epilepsy and their role in the OV329 clinical development program. The event will feature Dr. Alexander Rotenberg and discuss the use of biomarkers in drug development. OV329 aims to provide a novel treatment option for patients with treatment-resistant seizures.
Read more →OVIDOvid Therapeutics Reports Business Updates and First Quarter 2025 Financial Results Topline pharmacodynamic biomarker, safety and tolerability results from a Phase 1 study of OV329 are on track to readout in Q3 2025 Ovid
Ovid Therapeutics Reports Business Updates and First Quarter 2025 Financial Results Topline pharmacodynamic biomarker, safety and tolerability results from a Phase 1 study of OV329 are on track to readout in Q3 2025 Ovid's first program in its KCC2 direct activator library, OV3
Read more →OVIDOvid Therapeutics to Present at the 24th Annual Needham Virtual Healthcare Conference
Ovid Therapeutics announced that Meg Alexander, its President and COO, will present at the 24th Annual Needham Virtual Healthcare Conference on April 7, 2025. The event will showcase the company's efforts in developing therapies for neurological disorders. A live webcast will be available, with an archived replay accessible for 30 days post-event.
Read more →OVIDOvid Therapeutics Reports Business Updates and Fourth Quarter and Full Year 2024 Financial Results Stelios Papadopolous, Ph.D., a pioneering leader in biotech, appointed to Board of Directors two industry veterans joined
Ovid Therapeutics Reports Business Updates and Fourth Quarter and Full Year 2024 Financial Results Stelios Papadopolous, Ph.D., a pioneering leader in biotech, appointed to Board of Directors two industry veterans joined management team as Ovid prepares to take OV329 into patien
Read more →OVIDOvid Therapeutics Appoints Pioneering Industry Leader Dr. Stelios Papadopoulos to Board of Directors
NEW YORK, March 03, 2025 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (Nasdaq: OVID), a biopharmaceutical company dedicated to developing small-molecule medicines for brain conditions with significant unmet need, today announced the appointment of Stelios Papadopoulos, Ph.D. to its
Read more →OVIDOvid Therapeutics to Present at the TD Cowen 45th Annual Health Care Conference
NEW YORK, Feb. 27, 2025 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company dedicated to developing medicines for brain conditions with significant unmet need, today announced that Meg Alexander, President and Chief Operating Officer, will prese
Read more →OVIDOvid Therapeutics to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference
NEW YORK, Feb. 05, 2025 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (Nasdaq: OVID), a biopharmaceutical company dedicated to developing medicines for brain conditions with significant unmet need, today announced that management will participate in a virtual presentation at the Opp
Read more →OVIDOvid Therapeutics to Present Multiple Posters Supporting Its Pipeline Programs Targeting Neuronal Hyperexcitability at the American Epilepsy Society 2024 Annual Meeting
Two preclinical studies to be presented on OV329, a potential next-generation GABA aminotransferase inhibitor, highlighting its safety profile and lack of ocular accumulation relative to vigabatrin Findings to be presented on the effects of OV329 on elevating GABA and suppressin
Read more →OVIDOvid Therapeutics Reports Business Updates and Third Quarter 2024 Financial Results
A Phase 1 SAD/MAD study of OV329 is progressing as planned, and based on encouraging human safety data to date, Ovid will engage regulators about adding cohorts to increase potential dosing opportunities for Phase 2 programs. A regulatory application for a Phase 1 trial of OV350
Read more →OVIDOvid Therapeutics to Host Investor Event
NEW YORK, Oct. 31, 2024 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (Nasdaq: OVID), a biopharmaceutical company dedicated to improving the lives of people affected by rare epilepsies and brain conditions, today announced that it will host an investor event focused on its portfolio
Read more →OVIDOvid Therapeutics Presents Pre-Clinical Study Results Demonstrating OV329 Does Not Accumulate in Animal Eyes in Contrast with Vigabatrin
Study found OV329 cleared and remained undetectable in the retina, eye, and brain tissues of mice, unlike vigabatrin which has repeatedly shown to preferentially accumulate in mouse retinas, eyes, and other tissues OV329’s potency, mechanism of inhibition, short half-life, rapid
Read more →OVIDOvid Therapeutics to Present at Upcoming September Investor Conferences
NEW YORK, Sept. 04, 2024 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company dedicated to improving the lives of people affected by rare epilepsies and brain conditions, today announced that management will participate in two upcoming investor c
Read more →OVIDOvid Therapeutics Reports Business Updates and Second Quarter 2024 Financial Results
Appointed Dr. Amanda Banks, a tenured physician and biotech leader, as Chief Development Officer to lead clinical strategy and execution Expanded Scientific Advisory Board under the leadership of Dr. Robert Langer, adding top neurologists and neuroscientists to drive pipeline ad
Read more →OVIDOvid Therapeutics Appoints Dr. Amanda Banks, Experienced Biotech Leader & Physician as Chief Development Officer
NEW YORK, Aug. 08, 2024 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company dedicated to improving the lives of people affected by rare epilepsies and brain conditions, today announced the appointment of Amanda Banks, M.D., as Chief Development
Read more →OVIDOvid Therapeutics to Present at Upcoming August Investor Conferences
NEW YORK, July 30, 2024 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company dedicated to meaningfully improving the lives of people affected by certain epilepsies and brain conditions, today announced that management will participate in two upco
Read more →OVIDOvid Therapeutics Expands Scientific Advisory Board with Appointments of Leading Neurologists, Neuroscientists and Epileptologists
Neurologists/epileptologists Dr. Imad Najm of the Cleveland Clinic Neurological Institute and the Cleveland Clinic Epilepsy Center, and Dr. Raman Sankar, the Emeritus Chief of Pediatric Neurology at UCLA Health, appointed to Ovid’s Scientific Advisory Board (SAB) Neuroscientists
Read more →OVIDOvid Therapeutics and Graviton Bioscience Announce Topline Data from a Phase 1 Clinical Trial Studying OV888 GV101 Capsule, a Potential First-In-Class Therapy for Cerebral Cavernous Malformations The Phase 1 study for OV
Ovid Therapeutics and Graviton Bioscience Announce Topline Data from a Phase 1 Clinical Trial Studying OV888 GV101 Capsule, a Potential First-In-Class Therapy for Cerebral Cavernous Malformations The Phase 1 study for OV888 GV101 capsule met its objective demonstrating a favorab
Read more →OVIDOvid Therapeutics Reports on Takeda's Announcement of Phase 3 Topline Study Results for Soticlestat • Takeda's Skyline study in Dravet syndrome narrowly missed its primary endpoint of reduction in convulsive seizu
Ovid Therapeutics Reports on Takeda's Announcement of Phase 3 Topline Study Results for Soticlestat -Takeda's Skyline study in Dravet syndrome narrowly missed its primary endpoint of reduction in convulsive seizure frequency and showed clinically meaningful and significant effec
Read more →OVIDOvid Therapeutics Reports Business Updates and First Quarter 2024 Financial Results Takeda has completed two Phase 3 trials studying soticlestat as a treatment for Lennox-Gastaut syndrome and Dravet syndrome topline data
Ovid Therapeutics Reports Business Updates and First Quarter 2024 Financial Results Takeda has completed two Phase 3 trials studying soticlestat as a treatment for Lennox-Gastaut syndrome and Dravet syndrome topline data are anticipated in Takeda's H1 2024 fiscal year A Phase 1
Read more →OVIDOvid Therapeutics to Present at the H.C. Wainwright 2nd Annual BioConnect Investor Conference
NEW YORK, May 13, 2024 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company developing medicines designed to conquer epilepsies and meaningfully improve the lives of people affected by rare epilepsies and brain conditions, today announced that ma
Read more →OVIDOvid Therapeutics to Present at the 23rd Annual Needham Virtual Healthcare Conference
NEW YORK, April 04, 2024 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company dedicated to meaningfully improving the lives of people affected by rare epilepsies and brain conditions, today announced that management will participate in a virtual
Read more →OVIDOvid Therapeutics Reports Business Updates, Fourth Quarter and Full Year 2023 Financial Results Two pivotal Phase 3 clinical trials studying soticlestat as a treatment for Lennox-Gastaut syndrome (LGS) and Dravet syndrom
Ovid Therapeutics Reports Business Updates, Fourth Quarter and Full Year 2023 Financial Results Two pivotal Phase 3 clinical trials studying soticlestat as a treatment for Lennox-Gastaut syndrome (LGS) and Dravet syndrome (DS) completed enrollment Takeda anticipates topline data
Read more →OVIDOvid Therapeutics to Present at the TD Cowen 44th Annual Health Care Conference
NEW YORK, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company developing medicines designed to conquer epilepsies and meaningfully improve the lives of people affected by brain disorders, today announced that management will partic
Read more →OVIDOvid Therapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
NEW YORK, Feb. 06, 2024 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company developing medicines designed to conquer epilepsies and meaningfully improve the lives of people affected by brain disorders, today announced that management will partic
Read more →OVIDOvid Therapeutics to Present Five Abstracts Supporting its Epilepsy Programs at the 77th American Epilepsy Society Annual Meeting (2023)
Posters with new preclinical data on the pharmacokinetic and pharmacodynamic behavior of OV329 support its profile as a potential best-in-class GABA aminotransferase inhibitor Disease models provide further evidence characterizing OV350 and its anticipated seizure reduction and
Read more →OVIDOvid Therapeutics Reports Third Quarter 2023 Financial Results and Corporate Updates Received a $30 million payment from Ligand for the sale of a 13% interest in the potential future royalties and milestone payments owed
Ovid Therapeutics Reports Third Quarter 2023 Financial Results and Corporate Updates Received a $30 million payment from Ligand for the sale of a 13% interest in the potential future royalties and milestone payments owed to Ovid for soticlestat The Company extended its expected
Read more →OVIDOvid Therapeutics and Ligand Pharmaceuticals Enter into a $30 Million Agreement for a 13% Interest in Soticlestat Royalties and Milestones Extending Ovid's Cash Runway into 2026 • Ligand will receive 13% of all so
Ovid Therapeutics and Ligand Pharmaceuticals Enter into a $30 Million Agreement for a 13% Interest in Soticlestat Royalties and Milestones Extending Ovid's Cash Runway into 2026 -Ligand will receive 13% of all soticlestat royalties and milestone payments owed to Ovid -Ovid secu
Read more →OVIDOvid Therapeutics to Present at the Jefferies Biotech CNS/Neuro Summit
NEW YORK, Oct. 10, 2023 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with epilepsies and seizure-related disorders, today announced that management will participate in a
Read more →OVIDOVID R&D DAY OCTOBER 2, 2023 Dawn of the neurotherapeutics era Dr. Jeremy Levin CEO & Chairman Forward looking statement This presentation contains “forward-looking statements” within the meaning of the Pri
OVID R&D DAY OCTOBER 2, 2023 Dawn of the neurotherapeutics era Dr. Jeremy Levin CEO & Chairman Forward looking statement This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 including, without limitatio
Read more →OVIDOvid Therapeutics to Host Investor Event - R&D Day on Monday, October 2, 2023
NEW YORK, Sept. 26, 2023 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with epilepsies and seizure-related disorders, today announced that it will host a Research & Devel
Read more →OVIDOvid Therapeutics to Present at the 2023 Cantor Fitzgerald Global Healthcare Conference
NEW YORK, Sept. 20, 2023 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with epilepsies and seizure-related disorders, today announced that management will participate in
Read more →OVIDOvid Therapeutics to Participate in Upcoming September Investor Conferences
NEW YORK, Aug. 30, 2023 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with epilepsies and seizure-related disorders, today announced that management will participate in t
Read more →OVIDOvid Therapeutics Reports Second Quarter 2023 Financial Results and Corporate Updates Completed single ascending dose (SAD) portion of Phase 1 trial evaluating OV329, a potential next-generation GABA-aminotransferase inh
Ovid Therapeutics Reports Second Quarter 2023 Financial Results and Corporate Updates Completed single ascending dose (SAD) portion of Phase 1 trial evaluating OV329, a potential next-generation GABA-aminotransferase inhibitor Executed equity investment and initiated collaborat
Read more →OVIDOvid Therapeutics to Present at the BTIG Virtual Biotechnology Conference 2023
NEW YORK, Aug. 01, 2023 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with epilepsies and seizure-related disorders, today announced that management will participate in a
Read more →OVIDOvid Therapeutics Expands Its Scientific Leadership Team & Appoints Chief Strategy Officer
Dr. Zhong Zhong joins Ovid as Chief Scientific Officer (CSO) and Dr. Manoj Malhotra assumes role as Chief Medical Officer (CMO) following the planned retirement of Dr. Claude Nicaise Meg Alexander promoted to Chief Strategy Officer Ovid streamlined G&A infrastructure to improve
Read more →OVIDOvid Therapeutics Added to Russell 3000 Index
NEW YORK, June 26, 2023 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company developing medicines designed to conquer epilepsies and meaningfully improve the lives of people affected by brain disorders, today announced that the company was added
Read more →OVIDOvid Therapeutics Reports First Quarter 2023 Financial Results and Corporate Updates Initiated collaboration with Graviton Bioscience to develop selective ROCK2 inhibitors for rare neurological diseases Long-term data su
Ovid Therapeutics Reports First Quarter 2023 Financial Results and Corporate Updates Initiated collaboration with Graviton Bioscience to develop selective ROCK2 inhibitors for rare neurological diseases Long-term data supporting soticlestat safety, tolerability and seizure-redu
Read more →OVIDOvid Therapeutics Announces Collaboration with Graviton Bioscience, Proven Developers of Selective ROCK2 Inhibitors • Collaboration to unlock the therapeutic potential of ROCK2 inhibition for rare neurological dis
Ovid Therapeutics Announces Collaboration with Graviton Bioscience, Proven Developers of Selective ROCK2 Inhibitors -Collaboration to unlock the therapeutic potential of ROCK2 inhibition for rare neurological diseases -Couples Ovid capabilities in rare CNS development with Grav
Read more →OVIDLong-term Safety & Efficacy Findings from Soticlestat Open Label Extension Study Presented by Takeda at American Academy of Neurology Annual Meeting • Interim 2-year findings show soticlestat appeared generally sa
Long-term Safety & Efficacy Findings from Soticlestat Open Label Extension Study Presented by Takeda at American Academy of Neurology Annual Meeting -Interim 2-year findings show soticlestat appeared generally safe and well tolerated, consistent with prior studies -Sustained re
Read more →OVIDOvid Therapeutics to Present at the 22nd Annual Needham Virtual Healthcare Conference
NEW YORK, April 10, 2023 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with epilepsies and seizure-related disorders, today announced that management will present at the
Read more →OVIDOvid Therapeutics Reports Business Update, Fourth Quarter and Full Year 2022 Financial Results OV329 Phase 1 trial is progressing on track An IV formulation candidate suitable for future clinical trials has been achieved
Ovid Therapeutics recently reported its business update and financial results for 2022, highlighting positive progress in its OV329 Phase 1 trial and the successful formulation of OV350 for future clinical trials. The company's financial strategy includes cost-cutting measures and a cash runway expected to last into mid-2025. However, the financial results showed a notable decrease in revenue and a significant net loss compared to the previous year, largely influenced by one-time payments received in 2021. Ovid aims to improve its pipeline of anti-seizure medicines while mitigating risks with disciplined business development activities.
Read more →OVIDOvid Therapeutics to Present at the 2nd Annual Needham Virtual Neuroscience Forum
Ovid Therapeutics Inc. has announced its participation in the upcoming 2nd Annual Needham Virtual Neuroscience Forum on March 15, 2023. The presentation will focus on the company’s efforts to develop treatments for epilepsy and brain disorders, including the investigational drugs OV329 and OV350. A live webcast of the event will be available on Ovid's investor website. The company also holds important interests in the global development of soticlestat, which is currently in late-stage trials.
Read more →OVIDOvid Therapeutics to Present at the 43rd Annual Cowen Healthcare Conference
Ovid Therapeutics Inc. announced its participation in the Cowen 43rd Annual Healthcare Conference in Boston, where it will present a panel titled 'Orphan Epilepsies.' This event highlights Ovid's ongoing commitment to addressing the needs of individuals affected by epilepsies and brain disorders. The presentation will include insights into their research and development pipeline, which consists of novel therapies for treatment-resistant seizures and other epilepsy-related conditions.
Read more →OVIDOvid Therapeutics Expands Epilepsy Development Expertise with New Appointments
Ovid Therapeutics Inc. is expanding its medical and development team by appointing Dr. Manoj Malhotra as Chief Medical Officer and Dr. Toshiya Nishi as Head of Epilepsy Research. Dr. Malhotra brings significant experience in epilepsy clinical trials, having previously held senior roles at major pharmaceutical companies. Dr. Nishi collaborates with Ovid as a co-inventor of soticlestat and will concentrate on developing innovative epilepsy treatments. Both appointments aim to strengthen Ovid's leadership in developing therapies for seizures and brain disorders.
Read more →OVIDOvid Therapeutics Dosed Healthy Volunteers with OV329 in Phase 1 Trial
Ovid Therapeutics has started dosing healthy volunteers with OV329 in a Phase 1 trial to evaluate its safety and effectiveness for epilepsy treatment. OV329 is a GABA-aminotransferase inhibitor designed to reduce seizures in patients resistant to current therapies. The trial, conducted at Duke University, will measure various parameters including pharmacokinetics and target engagement. Results are expected in the first half of 2024, and the company aims to address significant unmet needs in the epilepsy community.
Read more →OVIDOvid Therapeutics to Present Data on Its Epilepsy Programs at American Epilepsy Society Annual Meeting (2022)
Preclinical data demonstrate potential efficacy and safety of OV329 at low, chronic dosing, suggesting an improved profile compared to other GABA-aminotransferase inhibitors Data from the NIH/NINDs Epilepsy Therapy Screening Program demonstrate that OV329 confers protection from
Read more →OVIDOvid Therapeutics Reports Third Quarter 2022 Financial Results and Corporate Highlights Ovid intends to initiate a Phase 1 study in healthy volunteers in Q4 2022, following the FDA clearance of an Investigational New Dru
Ovid Therapeutics Reports Third Quarter 2022 Financial Results and Corporate Highlights Ovid intends to initiate a Phase 1 study in healthy volunteers in Q4 2022, following the FDA clearance of an Investigational New Drug (IND) application for OV329, its GABA-aminotransferase in
Read more →OVIDOvid Therapeutics to Present at the Ladenburg Thalmann 2022 Healthcare Conference
NEW YORK, Sept. 27, 2022 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company developing medicines designed to conquer epilepsies and meaningfully improve the lives of people affected by brain disorders, today announced that management will prese
Read more →OVIDOvid Therapeutics to Present at the H.C. Wainwright 24th Annual Global Investment Conference
NEW YORK, Sept. 07, 2022 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company developing medicines designed to conquer epilepsies and meaningfully improve the lives of people affected by brain disorders, today announced that management will prese
Read more →OVIDOvid Therapeutics Reports Second Quarter 2022 Financial Results and Corporate Highlights Anticipates filing an Investigational New Drug application for OV329, a potent GABA-aminotransferase inhibitor, and initiating a Ph
Ovid Therapeutics Reports Second Quarter 2022 Financial Results and Corporate Highlights Anticipates filing an Investigational New Drug application for OV329, a potent GABA-aminotransferase inhibitor, and initiating a Phase 1 trial in the second half of 2022 Presented preclinic
Read more →OVIDOvid Therapeutics Presents Preclinical Data on OV329 at the Epilepsy Foundation Pipeline Conference
OV329 demonstrated robust anti-seizure activity in multiple preclinical seizure and epilepsy models, including treatment-resistant seizures Data demonstrate OV329 has the potential for an improved ocular safety profile and therapeutic index compared to other GABA-aminotransferas
Read more →OVIDOvid Therapeutics Reports First Quarter 2022 Financial Results and Corporate Highlights • Ovid anticipates filing an investigational new drug application (IND) for OV329, a potent GABA aminotransferase inhibitor,
Ovid Therapeutics Reports First Quarter 2022 Financial Results and Corporate Highlights -Ovid anticipates filing an investigational new drug application (IND) for OV329, a potent GABA aminotransferase inhibitor, and initiating Phase 1 trials in the fourth quarter of 2022 -Data
Read more →OVIDOvid Therapeutics to Present at the 21st Annual Needham Virtual Healthcare Conference
NEW YORK, April 08, 2022 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with epilepsies and seizure-related disorders, today announced that management will present at the
Read more →OVIDOvid Therapeutics Reports Business Update, Fourth Quarter and Full Year 2021 Financial Results • Ovid executing on its strategy to build a leading epilepsy pipeline • OV329 expected to enter the clinic in 2
Ovid Therapeutics Reports Business Update, Fourth Quarter and Full Year 2021 Financial Results -Ovid executing on its strategy to build a leading epilepsy pipeline -OV329 expected to enter the clinic in 2022 -Organization reshaped to reduce personnel by 20% and increase operat
Read more →OVIDOvid Therapeutics to Participate at the Cowen 42nd Annual Health Care Conference
NEW YORK, March 04, 2022 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people affected by epilepsies and rare neurological disorders, today announced that management will partic
Read more →OVIDOvid Therapeutics Expands Epilepsy Franchise with Novel KCC2 Activators Exclusive license from AstraZeneca adds a unique candidate and a broad library of compounds to Ovid's franchise of potential first-in-class anti-epi
Ovid Therapeutics Expands Epilepsy Franchise with Novel KCC2 Activators NEW YORK, January 3, 2022 -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological diseases, today ann
Read more →OVIDOvid Therapeutics Reports Third Quarter 2021 Business Update, Corporate Highlights and Financial Results Ovid is implementing its business development program which intends to secure a series of opportunities that comple
Ovid Therapeutics Reports Third Quarter 2021 Business Update, Corporate Highlights and Financial Results NEW YORK, November 10, 2021 Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rar
Read more →OVIDOvid Therapeutics Appoints Dr. Kevin Fitzgerald to Board of Directors
NEW YORK, Oct. 07, 2021 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological diseases, today announced that it has appointed Kevin Fitzgerald, Ph.D., to i
Read more →OVIDOvid Therapeutics to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
NEW YORK, Sept. 07, 2021 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with neurological diseases, today announced that management will present in a virtual format at the
Read more →OVIDDisclaimers and Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "may," "will," "believe," "expect
Disclaimers and Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "may," "will," "believe," "expect," "plan," "anticipate" and similar expressions (as well as
Read more →OVIDOvid Therapeutics Reports Second Quarter 2021 Financial Results and Corporate Highlights Company ends Q2 '21 with cash and cash equivalents of $212.2 million Recent appointments to Company leadership strongly position Ov
Ovid Therapeutics Reports Second Quarter 2021 Financial Results and Corporate Highlights NEW YORK, August 16, 2021 -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with neurological diseas
Read more →OVIDOvid Therapeutics Strengthens Board & Leadership Team to Focus Efforts on Expanding Its Neurosciences Capabilities
Dr. Michael Poole to Join the Board of Directors Dr. Claude Nicaise Appointed Head of R&D and Jason Tardio Appointed Chief Operating Officer Dr. Amit Rakhit to Join the Scientific and Clinical Advisory Board NEW YORK, July 08, 2021 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (N
Read more →OVIDOvid Therapeutics to Present at the Ladenburg Thalmann 2021 Healthcare Conference
NEW YORK, July 07, 2021 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological diseases, today announced that management will present in a virtual format at
Read more →OVIDDisclaimers and Forward-Looking Statements 2021 OVID THERAPEUTICS INC. | ALL RIGHTS RESERVED This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 199
These statements are based on the Company's current expectations and projections made by management and are not guarantees of future performance. Therefore, actual events, outcomes and results may differ materially from what is expressed or forecast in such forward-looking statem
Read more →OVIDOvid Therapeutics Appoints Jeff Rona as Chief Business and Financial Officer
NEW YORK, June 04, 2021 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological diseases, today announced that current Chief Business Officer Jeffrey Rona ha
Read more →OVIDOvid Therapeutics Appoints Dr. Joy A. Cavagnaro and Dr. Bruce A. Sullenger to its Scientific Advisory Board
New appointments strengthen neuroscience-focused Scientific Advisory Board NEW YORK, May 26, 2021 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological di
Read more →OVIDOvid Therapeutics Reports First Quarter 2021 Financial Results and Provides Corporate Update Closed royalty, license and termination agreement with Takeda for soticlestat; Ovid Therapeutics received an upfront payment of
Ovid Therapeutics Reports First Quarter 2021 Financial Results and Provides Corporate Update NEW YORK, May 13, 2021 - Ovid Therapeutics Inc. (NASDAQ: OVID) ("Ovid"), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurol
Read more →OVIDOvid Therapeutics to Participate in the 2021 RBC Capital Markets Global Healthcare Conference
NEW YORK, May 12, 2021 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological diseases, today announced that management will participate in a virtual firesi
Read more →OVIDOvid Therapeutics Announces Appointment of Professor Robert S. Langer, Sc.D., as Chair of its Scientific Advisory Board
NEW YORK, April 20, 2021 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological diseases, today announced that it has appointed Professor Robert S. Langer,
Read more →OVIDOVID Provides Update on OV101 Program and the Prioritization of its Resources Completed Soticlestat Agreement with Takeda Provides Significant Resources to Advance and Enrich OVID's Pipeline, Including OV882 for Angelman
OVID Provides Update on OV101 Program and the Prioritization of its Resources Completed Soticlestat Agreement with Takeda Provides Significant Resources to Advance and Enrich OVID's Pipeline, Including OV882 for Angelman Syndrome Company Reiterates Anticipated Quarterly Operati
Read more →OVIDOvid Therapeutics Announces Closing of Agreement with Takeda for Global Development and Commercialization of Soticlestat New York
Ovid Therapeutics Announces Closing of Agreement with Takeda for Global Development and Commercialization of Soticlestat New York, March 30, 2021 -Ovid Therapeutics Inc. (NASDAQ: OVID) ("Ovid"), a biopharmaceutical company committed to developing medicines that transform the liv
Read more →OVIDOvid Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results, Provides Corporate Update for 2021 Announced signing of transaction transferring Ovid's 50% of global rights to develop and commercialize sot
Ovid Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results, Provides Corporate Update for 2021 NEW YORK, March 15, 2021 - Ovid Therapeutics Inc. (NASDAQ: OVID) ("Ovid"), a biopharmaceutical company committed to developing medicines that transform the lives of
Read more →OVIDOvid Therapeutics Announces Addition to the Nasdaq Biotechnology Index
NEW YORK, Dec. 16, 2020 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological diseases, today announced that it has been added to the Nasdaq Biotechnology
Read more →OVIDOvid Therapeutics Announces Phase 3 NEPTUNE Clinical Trial of OV101 for the Treatment of Angelman Syndrome Did Not Meet Primary Endpoint • OV101 program in Angelman syndrome to pause pending full analysis of NEPTU
Ovid Therapeutics Announces Phase 3 NEPTUNE Clinical Trial of OV101 for the Treatment of Angelman Syndrome Did Not Meet Primary Endpoint NEW YORK, December 1, 2020 -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transf
Read more →OVIDOvid Therapeutics to Present at the American Epilepsy Society (AES) 2020 Virtual Congress
NEW YORK, Nov. 23, 2020 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological diseases, today announced that abstracts from the TAK-935/OV935 (soticlestat)
Read more →OVIDOvid Therapeutics Reports Third Quarter 2020 Financial Results and Provides Corporate Update • On track to report topline results from pivotal Phase 3 NEPTUNE trial of OV101 in Angelman syndrome in Q4 2020 •
Ovid Therapeutics Reports Third Quarter 2020 Financial Results and Provides Corporate Update NEW YORK, November 12, 2020 -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurologi
Read more →OVIDOvid Therapeutics to Host Educational Webinar on Angelman Syndrome and OV101 Development Program
NEW YORK, Oct. 14, 2020 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological diseases, today announced it will host an educational webinar on Thursday, Oc
Read more →OVIDOvid Therapeutics to Present at the Child Neurology Society/International Child Neurology Association (CNS/ICNA) Virtual Congress
Four abstracts from the OV101 (gaboxadol) clinical development program in Angelman Syndrome and Fragile X Syndrome to be presented NEW YORK, Oct. 12, 2020 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines tha
Read more →OVIDOvid Therapeutics Provides Soticlestat (OV935/TAK-935) Results from ARCADE and ENDYMION Studies Showing Seizure Reduction in Rare Epilepsies • Results from signal-finding, pilot Phase 2 open-label ARCADE study and
Ovid Therapeutics Provides Soticlestat (OV935/TAK-935) Results from ARCADE and ENDYMION Studies Showing Seizure Reduction in Rare Epilepsies NEW YORK, September 30, 2020 -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that
Read more →OVIDOvid Therapeutics to Present at the 2020 Cantor Fitzgerald Virtual Global Healthcare Conference
NEW YORK, Sept. 11, 2020 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological diseases, today announced that management will present at the 2020 Cantor Fi
Read more →OVIDPhase 2 ELEKTRA Study of Soticlestat (TAK-935/OV935) Meets Primary Endpoint Reducing Seizure Frequency in Children with Dravet Syndrome or Lennox-Gastaut Syndrome Primary endpoint achieved, demonstrating a s
Phase 2 ELEKTRA Study of Soticlestat (TAK-935/OV935) Meets Primary Endpoint Reducing Seizure Frequency in Children with Dravet Syndrome or Lennox-Gastaut Syndrome New York and Osaka, Japan, August 25, 2020 -- Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) ("Takeda") a
Read more →OVIDOvid Therapeutics Announces Pricing of $50 Million Offering of Common Stock
Ovid Therapeutics Announces Pricing of $50 Million Offering of Common Stock NEW YORK, August 25, 2020 (GLOBE NEWSWIRE) Ovid Therapeutics Inc. (Nasdaq: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of patients with rare neurologica
Read more →OVIDOvid Therapeutics Reports Second Quarter 2020 Financial Results and Provides Corporate Update • Announces completion of enrollment in the pivotal Phase 3 NEPTUNE trial with OV101 in Angelman syndrome; topline resu
Ovid Therapeutics Reports Second Quarter 2020 Financial Results and Provides Corporate Update NEW YORK, August 10, 2020 -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurologic
Read more →OVIDOvid Therapeutics to Participate at the William Blair Biotech Focus Conference 2020
NEW YORK, Aug. 05, 2020 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological diseases, today announced that Amit Rakhit, M.D., MBA, President and Chief Me
Read more →OVIDOvid Therapeutics and University of Connecticut Enter into Strategic Research Collaboration to Accelerate the Development of Next-Generation Genetic Therapy for Angelman Syndrome
Ovid to collaborate with renowned molecular geneticist and Angelman syndrome expert Stormy J. Chamberlain, Ph.D., to advance a short hairpin RNA (shRNA)-based therapeutic with the goal of addressing the underlying genetic cause of Angelman syndrome Ovid and UConn to collaborate
Read more →OVIDOvid Therapeutics and Angelini Pharma Enter into Exclusive License Agreement to Develop, Manufacture and Commercialize OV101 for the Treatment of Angelman Syndrome in Europe
Angelini Pharma obtains exclusive development, manufacturing and commercialization rights to OV101 (gaboxadol) for the potential treatment of Angelman syndrome in the European Union and other countries in the European Economic Area, and also Switzerland, Turkey, the United Kingdo
Read more →OVIDOvid Therapeutics Added to Russell 2000 and Russell 3000 Indexes
NEW YORK, June 29, 2020 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological diseases, today announced that it has been added to the Russell 2000® and the
Read more →OVIDOvid Therapeutics Receives FDA Rare Pediatric Disease Designation for OV101 for the Treatment of Angelman Syndrome
Ovid Therapeutics Receives FDA Rare Pediatric Disease Designation for OV101 for the Treatment of Angelman Syndrome NEW YORK, June 19, 2020 -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people w
Read more →OVIDJeremy Levin, DPhil, MB, BChir Chairman & Chief Executive Officer Ovid Therapeutics Welcome Disclaimers and Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the Priva
June 17, 2020 OV935 (soticlestat) Educational Seminar Exhibit 99.1 Jeremy Levin, DPhil, MB, BChir Chairman & Chief Executive Officer Ovid Therapeutics Welcome Disclaimers and Forward-Looking Statements This presentation contains forward-looking statements within the meaning of
Read more →OVIDOvid Therapeutics Announces Strategic Research Collaboration Focused on Accelerating the Development of New Treatments for Rare Neurological Diseases
Broad multiyear alliance with Columbia University Irving Medical Center researchers to focus on development of potential medicines using genetic based therapies and create a therapeutic platform for a range of rare neurological conditions Ovid to collaborate with renowned clinic
Read more →OVIDOvid Therapeutics Announces Multiple Presentations on the 2020 American Academy of Neurology Science Highlights Platform
NEW YORK, June 08, 2020 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological diseases, today announced multiple presentations across its rare neurological
Read more →OVIDOvid Therapeutics Launches Pipeline Teach-In Webinar Series
Company to host first webinar on Wednesday, June 17, to review OV935 (soticlestat) development program for rare developmental and epileptic encephalopathies (DEE) NEW YORK, June 04, 2020 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company commi
Read more →OVIDOvid Therapeutics Announces Participation in the 2020 RBC Capital Markets Virtual Global Healthcare Conference
NEW YORK, May 12, 2020 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological diseases, today announced that Amit Rakhit, M.D., MBA, President and Chief Med
Read more →OVIDOvid Therapeutics Announces Positive Topline Results from the Phase 2 ROCKET Trial of OV101 for the Treatment of Fragile X Syndrome
OV101 met the study’s primary objective of safety and tolerability OV101 produced statistically significant reductions in behavioral and functional symptoms in individuals with Fragile X syndrome Results support the continued development of OV101 in Fragile X syndrome NEW YORK
Read more →OVIDOvid Therapeutics Reports First Quarter 2020 Financial Results and Provides Corporate Update • Announced earlier today positive topline results from the Phase 2 ROCKET trial of OV101 for the treatment of Fragile X
Ovid Therapeutics Reports First Quarter 2020 Financial Results and Provides Corporate Update NEW YORK, May 7, 2020 -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological di
Read more →OVIDOvid Therapeutics Announces Initial Data with Soticlestat in CDKL5 Deficiency Disorder and Dup15q Syndrome Soticlestat continues to appear to be safe and well-tolerated; the majority of the 11 patients showed a reduction
Ovid Therapeutics Announces Initial Data with Soticlestat in CDKL5 Deficiency Disorder and Dup15q Syndrome Soticlestat continues to appear to be safe and well-tolerated; the majority of the 11 patients showed a reduction in seizures All patients that have completed the Phase 2
Read more →OVIDOvid Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results, Provides Corporate Update for 2020 • Multiple clinical data readouts across Ovid's pipeline expected in 2020 • Completed financ
Ovid Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results, Provides Corporate Update for 2020 NEW YORK, March 11, 2020 -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people w
Read more →OVIDOvid Therapeutics Announces Multiple Presentations at the American Academy of Neurology 2020 Annual Meeting
NEW YORK, March 05, 2020 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological diseases, today announced multiple poster presentations across its rare neur
Read more →OVIDOvid Therapeutics Names Alexander Kolevzon, M.D., to Scientific Advisory Board
NEW YORK, March 02, 2020 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological diseases, today announced the appointment of Alexander Kolevzon, M.D., a lea
Read more →OVIDOvid Therapeutics to Present at the Cowen and Company 40th Annual Health Care Conference
NEW YORK, Feb. 25, 2020 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological diseases, today announced that Jeremy Levin, DPhil, MB, BChir, Chairman and C
Read more →OVIDOvid Therapeutics Provides 2020 Update in Preparation for Multiple Clinical Data Readouts Across Rare Neurological Disease Platform OV101 (gaboxadol) in Neurodevelopmental Disorders: Topline Results From Pivotal Phase 3
Ovid Therapeutics Provides 2020 Update in Preparation for Multiple Clinical Data Readouts Across Rare Neurological Disease Platform OV101 (gaboxadol) in Neurodevelopmental Disorders: OV935/TAK935 (soticlestat) in Rare Developmental and Epileptic Encephalopathies (DEE): NEW YOR
Read more →OVIDOvid Therapeutics to Participate at the 31st Annual Piper Jaffray Healthcare Conference
NEW YORK, Nov. 26, 2019 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological diseases, today announced that Amit Rakhit, M.D., President and Chief Medical
Read more →OVIDOvid Therapeutics Appoints Jason Tardio as Chief Commercial Officer
Seasoned CNS and Rare Disease Commercial Executive Further Strengthens Executive Management Team NEW YORK, Nov. 18, 2019 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people wi
Read more →OVIDOvid Therapeutics Reports Third Quarter 2019 Financial Results and Recent Progress Announced Positive Initial Results from the Ongoing ENDYMION trial with OV935 (Soticlestat) in Rare Epilepsies; Sustained and Progressive
Ovid Therapeutics Reports Third Quarter 2019 Financial Results and Recent Progress Announced Positive Initial Results from the Ongoing ENDYMION trial with OV935 (Soticlestat) in Rare Epilepsies; Sustained and Progressively-Improving Median Seizure Frequency Reduction with Prolon
Read more →OVIDOvid Therapeutics Announces Senior Management Promotions in Preparation for Multiple Data Readouts Expected in 2020 Amit Rakhit, M.D., MBA, Promoted to President Timothy Daly Promoted to Executive Vice President, Finance
Ovid Therapeutics Announces Senior Management Promotions in Preparation for Multiple Data Readouts Expected in 2020 Amit Rakhit, M.D., MBA, Promoted to President Timothy Daly Promoted to Executive Vice President, Finance NEW YORK, November 01, 2019 - Ovid Therapeutics Inc. (NA
Read more →OVIDOvid Therapeutics Announces Pricing of $32.5 Million of Securities in Concurrent Public Offerings of Common Stock and Preferred Stock
Ovid Therapeutics Announces Pricing of $32.5 Million of Securities in Concurrent Public Offerings of Common Stock and Preferred Stock NEW YORK, Oct. 4, 2019 (GLOBE NEWSWIRE) Ovid Therapeutics Inc. (Nasdaq: OVID), a biopharmaceutical company committed to developing medicines th
Read more →OVIDOvid Therapeutics Announces Proposed Concurrent Public Offerings of Common Stock and Preferred Stock
NEW YORK, Oct. 03, 2019 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (Nasdaq: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of patients with rare neurological diseases, today announced that it intends to offer and sell shares of its c
Read more →OVIDOvid Therapeutics Announces Positive Initial Data from Ongoing ENDYMION Open-Label Extension Trial of Soticlestat in People with Rare Epilepsies
Sustained and Progressively-Improving Median Seizure Frequency Reduction Reaching 84-90% with Prolonged Treatment of Soticlestat in this Difficult-to-Treat Patient Population Soticlestat Continues to Advance in Rare Epilepsies; Initial Data from Phase 2 ARCADE Trial Anticipated
Read more →OVIDDisclaimers and Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "may," "will," "expect," "plan,"
Soticlestat (OV935) ENDYMION Update September 23, 2019 Exhibit 99.1 Disclaimers and Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "may," "will," "expect,"
Read more →OVIDOvid Therapeutics Announces First Patient Randomized in Pivotal Phase 3 NEPTUNE Trial of OV101 for the Treatment of Angelman Syndrome OV101 May Become the First Medicine for Individuals with Angelman Syndrome; Topline Re
Ovid Therapeutics Announces First Patient Randomized in Pivotal Phase 3 NEPTUNE Trial of OV101 for the Treatment of Angelman Syndrome OV101 May Become the First Medicine for Individuals with Angelman Syndrome; Topline Results Expected in Mid-2020 NEW YORK, September 12, 2019 -
Read more →OVIDOvid Therapeutics to Present at the H.C. Wainwright 21st Annual Global Investment Conference
NEW YORK, Sept. 09, 2019 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological diseases, today announced that Jeremey Levin, DPhil, MB, BChir, Chairman and
Read more →OVIDOvid Therapeutics Announces Participation in Two Upcoming Investor Conferences
NEW YORK, Sept. 03, 2019 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological diseases, today announced its participation in two upcoming investor confere
Read more →OVIDOvid Therapeutics Reports Second Quarter 2019 Financial Results and Highlights Recent Progress
Phase 3 NEPTUNE Trial of OV101 in Angelman Syndrome on Track to Enroll the First Patients in the Third Quarter of 2019 Regulatory Authorities in the U.S. and Germany agree that NEPTUNE, if positive, could support the filings of an NDA and MAA for OV101 Interim Data from Open-La
Read more →OVIDOvid Therapeutics (NASDAQ: OVID) is a New York-based biopharmaceutical company using its BoldMedicine approach to develop medicines that transform the lives of patients with rare neurological disorders. Ovid has a broad
Ovid Therapeutics Reports Second Quarter 2019 Financial Results and Highlights Recent Progress Phase 3 NEPTUNE Trial of OV101 in Angelman Syndrome on Track to Enroll the First Patients in the Third Quarter of 2019 Regulatory Authorities in the U.S. and Germany agree that NEPTUN
Read more →OVIDOvid Therapeutics Receives Orphan Drug Designation from the European Commission for OV101 for the Treatment of Angelman Syndrome
Ovid Therapeutics Receives Orphan Drug Designation from the European Commission for OV101 for the Treatment of Angelman Syndrome NEW YORK - July 2, 2019 - Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the live
Read more →OVIDOvid Therapeutics Initiates Pivotal Phase 3 Clinical Trial in Angelman Syndrome; Multiple Data Readouts Across Rare Neurological Disease Pipeline Expected in 2H 2019 and Early 2020 Phase 3 NEPTUNE Trial of OV101 Expected
Ovid Therapeutics Initiates Pivotal Phase 3 Clinical Trial in Angelman Syndrome; Multiple Data Readouts Across Rare Neurological Disease Pipeline Expected in 2H 2019 and Early 2020 Phase 3 NEPTUNE Trial of OV101 Expected to Enroll the First Patients in the Third Quarter of 2019;
Read more →OVIDOvid Therapeutics to Host R&D Day on
Ovid Therapeutics to Host R&D Day on June 27, 2019 Program to feature regulatory and clinical program updates and presentations from thought leaders on Angelman syndrome, Fragile X syndrome, and rare developmental and epileptic encephalopathies (DEE) NEW YORK - June 18, 2019 -
Read more →OVIDOvid Therapeutics to Host R&D Day on June 27, 2019
NEW YORK, June 18, 2019 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological disorders, today announced that it will host an R&D Day on Thursday, June 27,
Read more →OVIDCertain confidential information contained in this document, marked by brackets, is omitted because it is not material and would be competitively harmful if publicly disclosed. IN WITNESS WHEREOF , this Amendment is here
[***] = Certain confidential information contained in this document, marked by brackets, is omitted because it is not material and would be competitively harmful if publicly disclosed. THIS FIRST AMENDMENT TO LICENSE AGREEMENT (this "Amendment") is made as of this 10th day of Ma
Read more →OVIDOvid Therapeutics Reports First Quarter 2019 Financial Results Remains on track for all previously stated milestones expected throughout 2019 The STARS study selected as one of three abstracts featured at the 2019 AAN To
Ovid Therapeutics Reports First Quarter 2019 Financial Results Remains on track for all previously stated milestones expected throughout 2019 The STARS study selected as one of three abstracts featured at the 2019 AAN Top Science Press Conference NEW YORK - May 07, 2019 - Ovid
Read more →OVIDOvid Therapeutics to Present at the American Academy of Neurology 71st Annual Meeting
Emerging Science platform presentation highlights efficacy and safety data of OV101 in Angelman syndrome from the STARS study Research from Ovid’s Fragile X program shows new insights for outcome assessments NEW YORK, April 18, 2019 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (N
Read more →OVIDInvestors: Investor Relations & Public Relations Ovid Therapeutics Inc. irpr@ovidrx.com Alex Gray Burns McClellan, Inc. agray@burnsmc.com (212) 213-0006 Media: Jerica Pitts W2Opure jpitts@purecommunications.com
Ovid Therapeutics Announces Senior Management Changes to Align Expertise with Advancing Clinical Stage Pipeline NEW YORK - March 28, 2019 - Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people wit
Read more →OVIDOvid Therapeutics Announces Senior Management Changes to Align Expertise with Advancing Clinical Stage Pipeline
Ovid Therapeutics Announces Senior Management Changes to Align Expertise with Advancing Clinical Stage Pipeline NEW YORK - March 28, 2019 - Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people wit
Read more →OVIDOvid Therapeutics Announces Appointment of Pharmaceutical Veteran, Thomas Perone, as Senior Vice President, General Counsel and Corporate Secretary
Ovid Therapeutics Announces Appointment of Pharmaceutical Veteran, Thomas Perone, as Senior Vice President, General Counsel and Corporate Secretary NEW YORK - March 21, 2019 - Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines th
Read more →OVIDOvid Therapeutics Reports Fourth Quarter and Full Year 2018 Financial Results
Ovid Therapeutics Reports Fourth Quarter and Full Year 2018 Financial Results NEW YORK - March 7, 2019 - Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological disorders, toda
Read more →OVIDOvid Therapeutics to Present at the Cowen and Company 39th Annual Healthcare Conference on Monday, March 11
NEW YORK, March 04, 2019 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological diseases, today announced that Jeremy Levin, DPhil, MB BChir, Chairman and C
Read more →OVIDOvid Therapeutics Announces Pricing of $30 Million of Securities in Concurrent Public Offerings of Common and Preferred Stock
Ovid Therapeutics Announces Pricing of $30 Million of Securities in Concurrent Public Offerings of Common NEW YORK, February 20, 2019 (GLOBE NEWSWIRE) Ovid Therapeutics Inc. (Nasdaq: OVID), a biopharmaceutical company committed to developing medicines that transform the lives o
Read more →OVIDForward-Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "may," "will," "expect," "plan," "anticipate" and
Ovid Therapeutics Corporate Presentation February 2019 Exhibit 99.1 Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "may," "will," "expect," "plan," "anti
Read more →OVIDOvid Therapeutics Outlines 2019 Clinical and Business Priorities -- OV101 in Angelman syndrome : Pivotal Phase 3 NEPTUNE trial expected to begin in second half 2019 -- -- OV101 in Fragile X syndrome : Phase 2 ROCKET clin
Ovid Therapeutics Outlines 2019 Clinical and Business Priorities -- OV101 in Angelman syndrome: Pivotal Phase 3 NEPTUNE trial expected to begin in second half 2019 -- -- OV101 in Fragile X syndrome: Phase 2 ROCKET clinical trial results in adolescents and young adults expected
Read more →OVIDcollaboration with Takeda Pharmaceutical Company Limited for the treatment of rare developmental and epileptic encephalopathies (DEE). For more information on Ovid, please visit http://www.ovidrx.com/ . Forward-Looking S
Ovid Therapeutics Announces Phase 1b/2a Results of OV935/TAK-935 in Adults with Rare Epilepsies -- Met primary endpoint of safety and tolerability -- -- A dose-dependent reduction of plasma 24HC levels was observed, consistent with target engagement -- -- Exploratory analysis
Read more →OVIDOvid Therapeutics Announces Phase 1b/2a Results of OV935/TAK-935 in Adults with Rare Epilepsies
-- Met primary endpoint of safety and tolerability -- -- A dose-dependent reduction of plasma 24HC levels was observed, consistent with target engagement -- -- Exploratory analysis of clinical activity of OV935 shows a decrease in seizure frequency associated with the drop in 2
Read more →OVIDOvid Therapeutics Announces Plans to Move into a Phase 3 Trial in Pediatric Patients Based on End-of-Phase 2 Meeting for OV101 in Angelman Syndrome -- Single pivotal Phase 3 trial design, using once-daily dosing, may be
Ovid Therapeutics Announces Plans to Move into a Phase 3 Trial in Pediatric Patients Based on End-of-Phase 2 Meeting for OV101 in Angelman Syndrome -- Single pivotal Phase 3 trial design, using once-daily dosing, may be sufficient for approval of OV101 in Angelman syndrome-- --
Read more →OVIDOvid Therapeutics Announces OV935/TAK-935 Presentations at the American Epilepsy Society 72nd Annual Meeting
NEW YORK, Nov. 20, 2018 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological diseases, today announced that it will present two poster presentations and o
Read more →OVIDOvid Therapeutics to Present at 30th Annual Piper Jaffray Healthcare Conference on Tuesday, November 27
NEW YORK, Nov. 14, 2018 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological diseases, today announced that the company will present at the 30th Annual Pi
Read more →OVIDOvid Therapeutics Reports Third Quarter 2018 Financial Results and Highlights Recent Clinical Progress -- OV101 in Angelman syndrome: Plan to meet with U.S. FDA in the fourth quarter of 2018 to review Phase 2 STARS resul
Ovid Therapeutics Reports Third Quarter 2018 Financial Results and Highlights Recent Clinical Progress -- OV101 in Angelman syndrome: Plan to meet with U.S. FDA in the fourth quarter of 2018 to review Phase 2 STARS results and discuss next steps for program -- -- OV935/TAK-935
Read more →OVIDOvid Therapeutics Presents Additional Data and Analyses from the Phase 2 STARS Clinical Trial with OV101 for the Treatment of Angelman Syndrome at the 65th AACAP Annual Meeting
-- Additional data and analyses suggest that in the OV101 15 mg once-daily dose group, changes in sleep parameters and motor domains contributed to the statistically significant improvement in overall clinical global symptoms (CGI-I) observed in previously announced topline data
Read more →OVIDAbout Angelman Syndrome Angelman syndrome is a genetic disorder that is characterized by a variety of signs and symptoms. Characteristic features of this disorder include delayed development, intellectual disability, sev
Embargoed Until 10/25/2018 9am EDT Ovid Therapeutics Presents Additional Data and Analyses from the Phase 2 STARS Clinical Trial with OV101 for the Treatment of Angelman Syndrome at the 65th AACAP Annual Meeting -- Additional data and analyses suggest that in the OV101 15 mg on
Read more →OVIDOvid Therapeutics Receives “Company Making a Difference Award” from CDKL5 Deficiency Disorder Community
NEW YORK, Oct. 22, 2018 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological diseases, today announced it has received the 2018 CDKL5 Forum Company Making
Read more →OVIDOvid Therapeutics to Host Conference Call and Webcast on Thursday, October 25, at 10:30 a.m. EDT
-- Alexander Kolevzon, M.D., to review additional data from company’s Phase 2 STARS trial with OV101 for the treatment of Angelman syndrome during the 65th American Academy of Child and Adolescent Psychiatry (AACAP) Annual Meeting -- NEW YORK, Oct. 22, 2018 (GLOBE NEWSWIRE) -- O
Read more →OVIDovid-ex991_91.pptx.htm Corporate Presentation Cantor Fitzgerald Global Healthcare Conference
Corporate Presentation Cantor Fitzgerald Global Healthcare Conference October 1, 2018 Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "may," "will," "expect
Read more →OVIDOvid Therapeutics Announces Initiation of Two Phase 2 Clinical Trials of OV935/TAK-935 for Pediatric Patients with Rare Epilepsies
-- OV935 is being investigated for the treatment of pediatric patients with Dravet or Lennox-Gastaut syndromes in the ELEKTRA trial and pediatric patients with CDKL5 deficiency or Dup15q syndromes in the ARCADE trial -- NEW YORK, Sept. 24, 2018 (GLOBE NEWSWIRE) -- Ovid Therapeut
Read more →OVIDOvid Therapeutics to Present at Two Investor Healthcare Conferences in October 2018
NEW YORK, Sept. 19, 2018 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological diseases, today announced that the company will present at two upcoming inve
Read more →OVIDOvid Therapeutics to Present at Two Investor Healthcare Conferences in September 2018
NEW YORK, Aug. 29, 2018 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ:OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological diseases, today announced that the company will present at two upcoming invest
Read more →OVIDOvid Therapeutics Announces Phase 2 STARS Topline Data Accepted for Presentation at American Academy of Child And Adolescent Psychiatry Annual Meeting
- Poster presentation of STARS topline data: the first clinical trial to show a positive clinical benefit on overall Angelman syndrome impairments - NEW YORK, Aug. 16, 2018 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to deve
Read more →OVIDOvid Therapeutics Reports Second Quarter 2018 Financial Results and Highlights Recent Clinical Progress -- OV101 in Angelman syndrome: plan to initiate an open-label extension study (ELARA) in the fourth quarter of 2018
Ovid Therapeutics Reports Second Quarter 2018 Financial Results and Highlights Recent Clinical Progress -- OV101 in Angelman syndrome: plan to initiate an open-label extension study (ELARA) in the fourth quarter of 2018 and discuss with regulatory authorities next steps for a re
Read more →OVIDOvid Therapeutics Announces Positive Topline Data from Phase 2 STARS Trial of OV101 for the Treatment of Angelman Syndrome
-- OV101 achieved primary endpoint of safety and tolerability -- -- Robust and statistically significant improvement (p=0.0006) in the first prespecified efficacy endpoint (CGI-I) observed at 12 weeks of treatment in once-daily dose group compared to placebo -- -- STARS data su
Read more →OVIDAbout OV101 OV101 (gaboxadol) is believed to be the only delta ( )-selective GABA A receptor agonist in development and the first investigational drug to specifically target the disruption of tonic inhibition, a central
Ovid Therapeutics Announces Positive Topline Data from Phase 2 STARS Trial of OV101 for the Treatment of Angelman Syndrome -- OV101 achieved primary endpoint of safety and tolerability -- -- Robust and statistically significant improvement (p=0.0006) in the first prespecified e
Read more →OVIDAgenda SPEAKERS AGENDA ITEM Lora Pike Senior Director, IR & PR Welcome Jeremy Levin, DPhil, MB BChir Chairman & CEO Initial Remarks and OV101 Program Strategy Amit Rakhit, MD, MBA Chief Medical & Portfolio Management Off
Phase 2 STARS Trial Achieves Primary Endpoint and Shows Statistically Significant Improvements in CGI-I August 6, 2018 Exhibit 99.1 Agenda SPEAKERS AGENDA ITEM Lora Pike Senior Director, IR & PR Welcome Jeremy Levin, DPhil, MB BChir Chairman & CEO Initial Remarks and OV101 Progr
Read more →OVIDTakeda and Ovid Therapeutics Expand Clinical Program for TAK-935/OV935 with Three New Studies in Rare Developmental and Epileptic Encephalopathies (DEE) Broad clinical program to include three studies expected to begin i
Takeda and Ovid Therapeutics Expand Clinical Program for TAK-935/OV935 with Three New Studies in Rare Developmental and Epileptic Encephalopathies (DEE) Broad clinical program to include three studies expected to begin in the third quarter of calendar year 2018 in addition to th
Read more →OVIDOvid Therapeutics Announces Presentations Related to OV101 Fragile X Syndrome Program at the 16th National Fragile X Foundation (NFXF) International Conference
CINCINNATI, July 11, 2018 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ:OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological diseases, today announced several presentations related to the OV101 Fragile
Read more →OVIDOvid Therapeutics Announces Initiation of Phase 2 ROCKET Clinical Trial to Evaluate OV101 in Fragile X Syndrome Phase 2 trial will evaluate OV101 for 12 weeks in up to 30 males aged 13 to 22
Ovid Therapeutics Announces Initiation of Phase 2 ROCKET Clinical Trial to Evaluate OV101 in Fragile X Syndrome Phase 2 trial will evaluate OV101 for 12 weeks in up to 30 males aged 13 to 22 NEW YORK -July 11, 2018 - Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical co
Read more →OVIDOvid Therapeutics to Present at the Jefferies 2018 Global Healthcare Conference on June 8, 2018
NEW YORK, May 30, 2018 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ:OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological diseases, today announced that management will present a corporate overview at
Read more →OVIDOvid Therapeutics Announces Two Oral Presentations at the 14th Eilat Conference on New Antiepileptic Drugs and Devices (EILAT XIV)
New preclinical data provide further evidence of TAK-935/OV935’s novel mechanism of action, as a potential treatment for rare developmental and epileptic encephaolopathies (dEE) First presentation of preclinical data on OV329, a potential new therapeutic approach for treatment-r
Read more →OVIDOvid Therapeutics Reports First Quarter 2018 Financial Results and Corporate Progress - Data readouts for Ovid s two lead programs expected in 2018: OV101 STARS trial for adults and adolescents with Angelman syndrome (AS
Ovid Therapeutics Reports First Quarter 2018 Financial Results and NEW YORK May 8, 2018 Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological disorders, today reported finan
Read more →OVIDOvid Therapeutics to Present at Deutsche Bank’s 43rd Annual Health Care Conference on May 9, 2018
NEW YORK, May 02, 2018 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ:OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological disorders, today announced that management will present a corporate overview at
Read more →OVIDOvid Therapeutics Reports Fourth Quarter and Full Year 2017 Financial Results and Corporate Progress Enrollment Completed in Phase 2 STARS Clinical Trial in Adults and Adolescents with Angelman Syndrome; Topline Data Exp
Ovid Therapeutics Reports Fourth Quarter and Full Year 2017 Financial Results and Corporate Progress Enrollment Completed in Phase 2 STARS Clinical Trial in Adults and Adolescents with Angelman Syndrome; Topline Data Expected Third Enrollment Ongoing in Phase 1b/2a Clinical Tr
Read more →OVIDOvid Therapeutics to Host Fourth Quarter and Full Year 2017 Financial Results Conference Call on Thursday, March 29, 2018
NEW YORK, March 15, 2018 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ:OVID), a biopharmaceutical company committed to developing medicines for patients with rare neurological disorders, today announced that its fourth quarter and full year 2017 financial results will be rel
Read more →OVIDOvid Therapeutics Announces OV101 Granted Fast Track Designation by U.S. FDA for Treatment of Fragile X Syndrome
NEW YORK, March 15, 2018 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ:OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological diseases, today announced that the U.S. Food and Drug Administration (FDA) ha
Read more →OVIDOvid Therapeutics to Present at Two Upcoming Investor Conferences
NEW YORK, March 05, 2018 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ:OVID), a biopharmaceutical company committed to developing medicines for patients with rare neurological disorders, today announced that members of the company’s management team will present at two upcomi
Read more →OVIDOvid Therapeutics Announces Multiple Poster Presentations of OV101 and TAK-935/OV935 at the American Academy of Neurology 70th Annual Meeting
NEW YORK, March 01, 2018 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ:OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological diseases, today announced that it will present five poster presentations on O
Read more →OVIDOvid Therapeutics to Present at the RBC Capital Markets 2018 Global Healthcare Conference
NEW YORK, Feb. 15, 2018 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ:OVID), a biopharmaceutical company committed to developing medicines for patients with rare neurological disorders, today announced that Yaron Werber, MD, chief business and financial officer of Ovid, will
Read more →OVIDOvid Therapeutics Announces TAK-935/OV935 Granted Orphan Drug Designation by U.S. FDA for Treatment of Lennox-Gastaut Syndrome
NEW YORK, Dec. 20, 2017 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ:OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological diseases, today announced that the United States Food and Drug Administration
Read more →OVIDOvid Therapeutics Announces OV101 Granted Fast Track Designation by U.S. FDA for Treatment of Angelman Syndrome
NEW YORK, Dec. 19, 2017 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ:OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological diseases, today announced that the U.S. Food and Drug Administration (FDA) has
Read more →OVIDOvid Therapeutics Announces TAK-935/OV935 Has Received Orphan Drug Designation from U.S. FDA for Treatment of Dravet Syndrome
Ovid Therapeutics Announces TAK-935/OV935 Has Received Orphan Drug Designation from U.S. FDA for Treatment of Dravet Syndrome NEW YORK December 5, 2017 Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives
Read more →OVIDOvid Therapeutics Presents New Data Demonstrating Potential of TAK-935/OV935 as a Novel Treatment for Developmental and Epileptic Encephalopathies at the American Epilepsy Society (AES) Annual Meeting
- Phase 1 Clinical Trials of TAK-935/OV935 Demonstrated a Strong Safety Profile and Well Characterized Pharmacokinetic Profile, Supporting Further Clinical Advancement - - Results Support Plasma 24S-hydroxycholesterol (24HC) as a Potential Biomarker of TAK-935/OV935 Treatment -
Read more →OVIDOvid Therapeutics Announces OV101 Shows Comparable PK Profile in Phase 1 Study of Adolescent Patients and Amends Phase 2 STARS Clinical Trial Protocol to Include Adolescents Results from the Phase 1 Clinical Trial of Ado
Ovid Therapeutics Announces OV101 Shows Comparable PK Profile in Phase 1 Study of Adolescent Patients and Amends Phase 2 STARS Clinical Trial Protocol to Include Adolescents Results from the Phase 1 Clinical Trial of Adolescents with Angelman and Fragile X Syndromes Demonstra
Read more →OVIDOvid Therapeutics Announces Five Poster Presentations on TAK-935/OV935 at the American Epilepsy Society 71st Annual Meeting
NEW YORK, Nov. 21, 2017 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ:OVID), a biopharmaceutical company committed to developing medicines for patients with rare neurological diseases, today announced that it will present five poster presentations on TAK-935/OV935 at the Ame
Read more →OVIDOvid Therapeutics to Participate in Two Upcoming Investor Conferences
NEW YORK, Nov. 20, 2017 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ:OVID), a biopharmaceutical company committed to developing medicines for patients with rare neurological disorders, today announced that it will participate in two upcoming investor conferences: 29th Annu
Read more →OVIDOvid Therapeutics Reports Third Quarter 2017 Financial Results and Corporate Progress
Ovid Therapeutics Reports Third Quarter 2017 Financial Results and Corporate Progress NEW YORK November 9, 2017 - Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines for patients with rare neurological diseases, today announced f
Read more →OVIDOvid Therapeutics to Participate at the Stifel 2017 Healthcare Conference
NEW YORK, Nov. 08, 2017 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ:OVID), a biopharmaceutical company committed to developing medicines for patients with rare neurological disorders, today announced that Jeremy Levin, DPhil, MB BChir, chairman and chief executive officer,
Read more →OVIDOvid Therapeutics Announces Positive Preclinical OV101 Data Demonstrating Behavioral Improvements in Fragile X Syndrome Model
Ovid Therapeutics Announces Positive Preclinical OV101 Data Demonstrating Behavioral Improvements in Fragile X Syndrome Model NEW YORK October 16, 2017 - Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines for patients with rare
Read more →OVIDOvid Therapeutics Receives Orphan Drug Designation from the U.S. FDA for OV101 for Treatment of Fragile X Syndrome
Ovid Therapeutics Receives Orphan Drug Designation from the U.S. FDA for OV101 for Treatment of Fragile X NEW YORK October 10, 2017 - Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rar
Read more →OVIDOvid Therapeutics to Present Preclinical Data Demonstrating OV101 Normalizes Behavioral Abnormalities at the 18th International Fragile X and Related Neurodevelopmental Disorders Workshop
NEW YORK, Oct. 05, 2017 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ:OVID), a biopharmaceutical company committed to developing medicines for patients with rare neurological diseases, today announced that it will provide a poster presentation of preclinical data on OV101, a
Read more →OVIDOvid Therapeutics Appoints Ana C. Ward as Senior Vice President and General Counsel
NEW YORK, Sept. 06, 2017 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ:OVID), a biopharmaceutical company committed to developing medicines for patients with rare neurological disorders, today announced the appointment of Ana C. Ward as senior vice president and general coun
Read more →OVIDOvid Therapeutics Announces First Patient Randomized in Phase 1b/2a Clinical Trial of TAK-935/OV935 in Adults with Rare Epilepsies
- Cornerstone of Robust Clinical Development Strategy for Potential First-in-Class CH24H Modulator - - Ovid’s Clinical Pipeline of Rare Neurological Disorder Programs Advancing to Mid-Stage Trials - NEW YORK, Aug. 21, 2017 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ:OV
Read more →OVIDForward-Looking Statements This presentation contains projections for Ovid Therapeutics Inc. ("Ovid") and other forward-looking information. Such projections and information are based on assumptions as to future events t
Corporate Presentation August 15, 2017 Forward-Looking Statements This presentation contains projections for Ovid Therapeutics Inc. ("Ovid") and other forward-looking information. Such projections and information are based on assumptions as to future events that are inherently
Read more →OVIDOvid Therapeutics Reports Second Quarter 2017 Financial Results and Corporate Progress
Ovid Therapeutics Reports Second Quarter 2017 Financial Results and Corporate Progress NEW YORK August 10, 2017 Ovid Therapeutics Inc. (NASDAQ:OVID), a biopharmaceutical company committed to developing medicines for patients with rare neurological disorders, today announced fin
Read more →OVIDOvid Therapeutics to be Added to Russell 2000 , 3000 and Microcap Indexes
NEW YORK, June 23, 2017 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ:OVID), a biopharmaceutical company committed to developing medicines for patients with rare neurological disorders, today announced that it will be added to the Russell 2000®, 3000® and Microcap® Indexes,
Read more →OVIDOvid Therapeutics Appoints Barbara G. Duncan to its Board of Directors Ms. Duncan to serve as chairperson of Audit Committee
Ovid Therapeutics Appoints Barbara G. Duncan to its Board of Directors Ms. Duncan to serve as chairperson of Audit Committee NEW YORK June 14, 2017 Ovid Therapeutics Inc. (NASDAQ:OVID), a biopharmaceutical company committed to developing medicines for patients with rare neurol
Read more →OVIDOvid Therapeutics Reports First Quarter 2017 Financial Results and Recent Corporate Progress Completed Initial Public Offering Raising $75 Million in Gross Proceeds Initiated Phase 2 STARS Clinical Trial of OV101 in Adul
Ovid Therapeutics Reports First Quarter 2017 Financial Results and Recent Completed Initial Public Offering Raising $75 Million in Gross Proceeds Initiated Phase 2 STARS Clinical Trial of OV101 in Adults with Angelman Syndrome Entered into Innovative Global Collaboration with
Read more →OVIDOvid Therapeutics to Participate in the JMP Securities 2017 Life Sciences Conference
NEW YORK, June 12, 2017 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ:OVID), a biopharmaceutical company committed to developing medicines for patients with rare neurological disorders, today announced that Yaron Werber, MD, chief business and financial officer of Ovid, will
Read more →OVIDOvid Therapeutics to Present Preclinical Data on TAK-935/OV935 at the Antiepileptic Drug and Device Trials XIV Conference
NEW YORK, May 12, 2017 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc., (NASDAQ:OVID) a biopharmaceutical company committed to developing medicines for patients with rare neurological diseases, today announced that it will present preclinical data on TAK-935/OV935, a potent and highly
Read more →OVIDOvid Therapeutics Inc. (Nasdaq: OVID) to Ring The Nasdaq Stock Market Closing Bell
ADVISORY, May 09, 2017 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (Nasdaq:OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological diseases, will visit the Nasdaq MarketSite in Times Square. In honor of the o
Read more →OVIDOvid Therapeutics Announces Pricing of Initial Public Offering
NEW YORK, May 04, 2017 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc., a biopharmaceutical company, announced today that it has priced its initial public offering of 5,000,000 shares of its common stock at a public offering price of $15.00 per share, for an aggregate offering of $75
Read more →OVIDOvid Therapeutics Announces Initiation of Phase 1 Clinical Trial of OV101 for Adolescents with Angelman Syndrome or Fragile X Syndrome
NEW YORK, April 10, 2017 (GLOBE NEWSWIRE) -- Ovid Therapeutics, Inc., a privately held biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological diseases, today announced that it has initiated a Phase 1 clinical trial to
Read more →OVIDOvid Therapeutics and NeuroPointDX Announce Collaboration to Identify Biomarkers for Angelman Syndrome
NEW YORK and MADISON, Wis., Feb. 09, 2017 (GLOBE NEWSWIRE) -- Ovid Therapeutics, a privately held biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological disorders, and NeuroPointDX, a privately held biotech company ba
Read more →OVIDOvid Therapeutics Announces First Patient Randomized in the Phase 2 STARS Clinical Trial in Adults with Angelman Syndrome
NEW YORK, Feb. 09, 2017 (GLOBE NEWSWIRE) -- Ovid Therapeutics, a privately held biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological disorders, today announced it has randomized the first patient in its STARS trial
Read more →OVIDOvid Therapeutics Names Jacqueline A. French, M.D. to Scientific Advisory Board
NEW YORK, Jan. 19, 2017 (GLOBE NEWSWIRE) -- Ovid Therapeutics, a privately held biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological diseases, today announced the appointment of Jacqueline A. French, M.D., a world-r
Read more →Competitive Position
How OVID ranks across every disease it competes inCompetitive Position is a premium feature
See how OVID ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial